129 related articles for article (PubMed ID: 36135951)
21. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
23. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
[TBL] [Abstract][Full Text] [Related]
24. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
25. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
[TBL] [Abstract][Full Text] [Related]
26. Multiple total hip arthroplasties in refractory immune thrombocytopenic purpura: A case report and literature review.
Tang Y; Xu Y; Shi Z; Ma X; Fan L; Wang K; Dang X
Medicine (Baltimore); 2018 Apr; 97(15):e0308. PubMed ID: 29642159
[TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
[TBL] [Abstract][Full Text] [Related]
28. Hsa_circ_0008301 as a potential biomarker of disease activity for primary Sjogren's syndrome: Increased expression in peripheral blood of patients with primary Sjogren's syndrome.
Ji J; Zhang X; Ling Y; Tian J; Wang Y; Luo Y; Zhu R; Zhou Y; Zhu T; Wang L; Zhu H
Int Immunopharmacol; 2022 Nov; 112():109231. PubMed ID: 36113315
[TBL] [Abstract][Full Text] [Related]
29. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome.
Chen C; Liang Y; Zhang Z; Zhang Z; Yang Z
Int Immunopharmacol; 2020 Nov; 88():106878. PubMed ID: 32791244
[TBL] [Abstract][Full Text] [Related]
30. Autoantibody to MDM2: A potential serological marker of primary Sjogren's syndrome.
Liu Y; Liao X; Wang Y; Chen S; Sun Y; Lin Q; Shi G
Oncotarget; 2017 Feb; 8(9):14306-14313. PubMed ID: 28147328
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
[TBL] [Abstract][Full Text] [Related]
32. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
Front Immunol; 2019; 10():1527. PubMed ID: 31354708
[No Abstract] [Full Text] [Related]
33. Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.
He J; Chen J; Miao M; Zhang R; Cheng G; Wang Y; Feng R; Huang B; Luan H; Jia Y; Jin Y; Zhang X; Shao M; Wang Y; Zhang X; Li J; Zhao X; Wang H; Liu T; Xiao X; Zhang X; Su Y; Mu R; Ye H; Li R; Liu X; Liu Y; Li C; Liu H; Hu F; Guo J; Liu W; Zhang WB; Jacob A; Ambrus JL; Ding C; Yu D; Sun X; Li Z
JAMA Netw Open; 2022 Nov; 5(11):e2241451. PubMed ID: 36355371
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
35. IL-14α as a Putative Biomarker for Stratification of Dry Eye in Primary Sjögren's Syndrome.
Liang Y; Xian Z; Fu D; Liu S; Yao Y; Jin Y; Gao C; Shen L; Shi G; He J
Front Immunol; 2021; 12():673658. PubMed ID: 34012457
[TBL] [Abstract][Full Text] [Related]
36. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
[TBL] [Abstract][Full Text] [Related]
37. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
38. Elevated CXCL13 in primary Sjögren's syndrome and its correlation with disease activity: a systematic review and meta-analysis.
Zhu T; Pan Z; Zhang N
Clin Rheumatol; 2022 Sep; 41(9):2791-2802. PubMed ID: 35616754
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
[TBL] [Abstract][Full Text] [Related]
40. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
